IOL Chemicals & Pharmaceuticals Ltd Q1 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/1uct2jc47enxh0akl1k4gub9.pdf

Key Takeaways


Financial Performance & Margin Walk

Dr. Sanjay Chaturvedi: "So, you know, it's a game of inches actually where we have gone from about 8.5 to 8.7% to 11% in one quarter. So, we do feel confident that by the end of the year, we will be back to between 15 and 20%."

Non-Ibuprofen Pharma Portfolio

Dr. Sanjay Chaturvedi: "If price was the only criteria, then I guess we would all be driving Tata Nano. So, you know, there is some value in long term relationships..."

CAPEX & Strategic Expansion

Dr. Sanjay Chaturvedi: "I think a CAPEX investment in challenging environment, actually is a testament of our confidence and our ability to create value out of the CAPEX that we put in."

Segment Mix & Diversification


Demand Environment & End-Markets

Dr. Sanjay Chaturvedi: "So, you clearly understand this game Gautam that to get approvals in regulated markets is not a question of months and quarters. It's a question of years and this is a journey we started several years ago."

Regulatory & Product Pipeline


Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin recoveryReturn to 15–20% EBITDA marginBy end of FY23
New plant CAPEX completion₹300 crores investment in western India plantWithin 18 months
Ethyl acetate capacity expansionIncrease from 100,000 to ~120,000 metric tons per annumBy end of FY23
Non-ibuprofen pharma shareReach ~50% of pharma segmentWithin next year to year-and-a-half
Ibuprofen share of API businessDecline to ~50% of total API businessWithin next year or so
DMF filing cadenceFile five to six DMFs every yearOngoing, annually
Ibuprofen capacity utilizationMove beyond 75% utilizationComing few quarters
Non-ibuprofen profitability improvementHigher asset utilization and greater export shareAnother couple of quarters

Key Metrics

MetricQ1 FY23
Total income₹570 cr, vs ₹524 cr in Q1 FY22 and ₹579 cr in Q4 FY22
EBITDA₹61 cr, vs ₹116 cr in Q1 FY22 and ₹50 cr in Q4 FY22
EBITDA margin10.7%, vs 8.6% in Q4 FY22
Net profit₹34.9 cr, vs ₹67 cr in Q1 FY22 and ₹27.8 cr in Q4 FY22
Chemicals segment EBIT margin16%, vs 5% in Q1 FY22 and negative 2% in Q4 FY22
Pharma segment EBIT margin23%, vs 12% in Q1 FY22 and 30% in Q4 FY22
Cash and cash equivalents~₹300 cr as of June 30, 2022
Short-term debt~₹400 cr; no long-term debt on books
Planned CAPEX for new plant~₹300 cr, to be funded primarily through internal accruals with possible small debt
Ibuprofen capacity utilization70–75%
Ibuprofen pricing$11–$12 per kilo
Ibuprofen volume~800 tons per month
Ibuprofen capacity market share (India)33–35%; sales-wise market share ~30%
Non-ibuprofen share of total business35–40%, up from ~15% two years ago; target ~50% in next year to year and a half
Export contribution to overall sales25%, down from 38–39% previously, driven by chemicals segment where international ethyl acetate prices are lower than domestic
Ethyl acetate capacity100,000 metric tons per annum; expansion to 120,000 MT by end of FY23 (20% increase)
Ethyl acetate pricing changeDown ~15% in Q1 FY23 vs Q4 FY22
DMFs filed in Q1 FY233; plan to file 5–6 DMFs every year